INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Sauvage Philippe reported NUVB

Chief Financial Officer · Nuvation Bio Inc. · Nuvation Bio Inc. — Stock Option (Right to Buy)

Side
M
Value
—
Shares
47.7K
Price
—
Executed
Jun 23, 2026
Disclosed
Jun 24, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 23 executedJun 24, 2026 disclosed

NUVB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
3/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 7.3% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NUVB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    14
    SP
    Sauvage PhilippeChief Financial Officer
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M$103K
    47.7K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    28
    SP
    Sauvage PhilippeChief Financial Officer
    NUVBNuvation Bio Inc.
    Open-market sale · 10b5-1 plan
    		SELL$286K
    47.7K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    14
    MS
    Markel StacyCHIEF PEOPLE OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M$169K
    90.4K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    10
    MS
    Markel StacyCHIEF PEOPLE OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M$60K
    34.6K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    28
    MS
    Markel StacyCHIEF PEOPLE OFFICER
    NUVBNuvation Bio Inc.
    Open-market sale · 10b5-1 plan
    		SELL$753K
    125.0K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    7
    MS
    Markel StacyCHIEF PEOPLE OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M—
    90.4K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    3
    MS
    Markel StacyCHIEF PEOPLE OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M—
    34.6K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    36
    MR
    Mashal RobertDirector
    NUVBNuvation Bio Inc.
    Open-market purchase
    		BUY$118K
    25.0K sh
    		Jun 9, 2026Jun 11, 2026
    traded Jun 9, 2026
    		+2dSEC FORM 4

    Evidence

    15
    MR
    Mashal RobertDirector
    NUVBNuvation Bio Inc.
    Grant or award
    		A—
    123.4K sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    0
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M—
    50.0K sh
    		Apr 17, 2026Apr 21, 2026
    traded Apr 17, 2026
    		+4dSEC FORM 4

    Evidence

    10
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise · 10b5-1 plan
    		M$97K
    50.0K sh
    		Apr 17, 2026Apr 21, 2026
    traded Apr 17, 2026
    		+4dSEC FORM 4

    Evidence

    19
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Open-market sale · 10b5-1 plan
    		SELL$251K
    50.0K sh
    		Apr 17, 2026Apr 21, 2026
    traded Apr 17, 2026
    		+4dSEC FORM 4

    Evidence

    17
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M$36K
    10.0K sh
    		Nov 26, 2025Nov 26, 2025
    traded Nov 26, 2025
    		+0dSEC FORM 4

    Evidence

    33
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Open-market sale
    		SELL$80K
    10.0K sh
    		Nov 26, 2025Nov 26, 2025
    traded Nov 26, 2025
    		+0dSEC FORM 4

    Evidence

    5
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M—
    10.0K sh
    		Nov 26, 2025Nov 26, 2025
    traded Nov 26, 2025
    		+0dSEC FORM 4

    Evidence

    5
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M—
    10.0K sh
    		Nov 25, 2025Nov 26, 2025
    traded Nov 25, 2025
    		+1dSEC FORM 4

    Evidence

    33
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Open-market sale
    		SELL$75K
    10.0K sh
    		Nov 25, 2025Nov 26, 2025
    traded Nov 25, 2025
    		+1dSEC FORM 4

    Evidence

    17
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M$36K
    10.0K sh
    		Nov 25, 2025Nov 26, 2025
    traded Nov 25, 2025
    		+1dSEC FORM 4

    Evidence

    17
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M$37K
    20.0K sh
    		Nov 20, 2025Nov 24, 2025
    traded Nov 20, 2025
    		+4dSEC FORM 4

    Evidence

    5
    LD
    Liu DongfangCHIEF MEDICAL OFFICER
    NUVBNuvation Bio Inc.
    Option exercise
    		M—
    20.0K sh
    		Nov 20, 2025Nov 24, 2025
    traded Nov 20, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002039891-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 23, 2026
    Published
    Jun 24, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Sauvage Philippe
    Role
    Chief Financial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Nuvation Bio Inc. — Stock Option (Right to Buy)
    Ticker
    NUVB
    Shares
    47.7K
    Price per share
    $0
    Execution date (reported)
    Jun 23, 2026
    Owned after transaction
    702.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    What this establishes

    Sauvage Philippe filed this Form 4 reporting a option exercise of NUVB on Jun 23, 2026. It became public on Jun 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Sauvage Philippecik:0002039891
    Issuer
    Nuvation Bio Inc.cik:0001811063

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.